The FDA cleared marketing for the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer disease.

The Lumipulse G Plasma Ratio Test offers a new way to detect signs of Alzheimer's disease by identifying plaque proteins in ...

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s ...

The US Food and Drug Administration (FDA) has awarded 510(k) clearance to Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 ...

The Lumipulse Alzheimer's blood test is the first of a new generation of tests that may replace brain scans and spinal taps to detect the disease.

The FDA has cleared the first-ever blood test for early Alzheimer's detection, which the agency says reduces the need for ...

The US Food and Drug Administration has given marketing clearance to a blood test to help diagnose Alzheimer’s disease, ...

Japan-based Fujirebio's test, which helps doctors diagnose Alzheimer's disease, is intended for patients with signs of ...

The U.S. Food and Drug Administration (USFDA) has cleared for marketing the first in vitro diagnostic device that tests blood ...

The U.S. Food and Drug Administration on Friday approved a new blood test for the early detection of Alzheimer's disease in ...

The FDA cleared the test for the early detection of amyloid plaques associated with Alzheimer’s in people aged 55 years and ...

The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio enables early detection of amyloid plaques through a non-invasive blood ...